No. Ingredient position alone generally cannot establish an exact percentage in an ordinary U.S. cosmetic. Rank is not a concentration measurement. FDA ingredient-name guidance.
Order rules and their exceptions
FDA describes retail cosmetic ingredient lists as generally descending by predominance. FDA retail-label explanation.
Its labeling summary permits color additives and ingredients present at 1% or less to appear without predominance ordering. Those exceptions matter before interpreting any position. FDA ordering exceptions.
A fictional rank-and-amount sketch
Assume fictional ingredients A, B and C occupy a descending-order segment. This is a reasoning example, not a product label or measured formula.
| Fictional ingredient | Assumed rank | Exact amount |
|---|---|---|
| A | First | Not provided |
| B | Second | Not provided |
| C | Third | Not provided |
A can be at least as abundant as B, and B as C, without fixing their amounts. Different gaps can preserve the ranking: the constraint does not select one formula. This is an editorial inference from the ordering principle. FDA ordering context.
A paraben is not a percentage marker
The captured exceptions concern ingredient category or amount, not a paraben’s position. They do not support treating that position as a universal 1% boundary. This is an inference, not an additional FDA rule. FDA exception wording.
Drug-cosmetic labels and missing documentation
For cosmetics that are also drugs, FDA’s summary places identified active drug ingredients before cosmetic ingredients. Do not read that combined sequence as one concentration ranking. FDA drug-cosmetic distinction.
A focused manufacturer question is: Can you document this ingredient’s concentration in this exact product version? Record an unanswered amount as unknown. Keep any supplied percentage with its document, product identity and date; do not substitute a position-based estimate.
Source check date: October 26, 2026, using supplied FDA captures, not a live check. Refresh this explanation if the cited rules change. No product concentrations, efficacy or allergy suitability were assessed.
